

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Gastrointestinal Cancers (Webinar Video Proceedings)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements best describes outcomes with encorafenib, binimetinib and cetuximab as second-line treatment for patients with metastatic colorectal cancer (mCRC)?**
 - a. Overall survival (OS) with the doublet encorafenib/cetuximab is significantly better than with the triplet
 - b. OS with the triplet combination is significantly better than with the doublet
 - c. OS is equivalent with the doublet and triplet regimens**
- 2. The ongoing Phase II MOUNTAINEER study is evaluating the addition of which of the following agents to trastuzumab for patients with HER2-amplified mCRC?**
 - a. Trastuzumab deruxtecan
 - b. Tucatinib**
 - c. T-DM1
 - d. Pertuzumab
 - e. Sotorasib
- 3. Data from GALAXY, an observational study monitoring minimal residual disease, presented by Kotaka and colleagues at the Gastrointestinal Cancers Symposium 2022, revealed which correlation between detection of postoperative circulating tumor DNA (ctDNA) and outcomes with adjuvant chemotherapy among patients with high-risk Stage II and Stage III colon cancer?**
 - a. Adjuvant chemotherapy is associated with improved disease-free survival (DFS) for patients with detectable postoperative ctDNA**
 - b. Adjuvant chemotherapy is not associated with improved DFS for patients with detectable postoperative ctDNA
 - c. No correlation was observed between ctDNA levels and outcomes with adjuvant chemotherapy
- 4. What is the target of the novel antibody zolbetuximab?**
 - a. PD-1
 - b. PD-L1
 - c. VEGF
 - d. CLDN 18.2**
- 5. The Phase III IMbrave150 study comparing the combination of atezolizumab and bevacizumab to sorafenib for patients with advanced hepatocellular carcinoma revealed which of the following survival outcomes with the combination?**
 - a. Improvement in progression-free survival (PFS) only
 - b. Improvement in OS only
 - c. Improvement in PFS and OS**
 - d. No improvement in either PFS or OS